Acquired cystic fibrosis transmembrane conductance regulator dysfunction in chronic bronchitis and other diseases of mucus clearance
SV Raju, GM Solomon… - Clinics in chest …, 2016 - chestmed.theclinics.com
New therapies are needed for the treatment of chronic obstructive pulmonary disease
(COPD), which accounts for more than $30 billion in annual health care costs, 1 and recently
surpassed stroke as the third leading cause of death in the United States. 2 Although
smoking cessation is essential to slow the progression of disease, no current
pharmaceuticals alter the natural history of the disease or improve the mucus retention that
is characteristic of COPD, persists even in ex-smokers, and is independently associated with …
(COPD), which accounts for more than $30 billion in annual health care costs, 1 and recently
surpassed stroke as the third leading cause of death in the United States. 2 Although
smoking cessation is essential to slow the progression of disease, no current
pharmaceuticals alter the natural history of the disease or improve the mucus retention that
is characteristic of COPD, persists even in ex-smokers, and is independently associated with …